MegaNano BioTech Inc.
Our goal is to develop the best immunotherapies for neurodegenerative disease and cancers including vaccines, antibodies.
Our US-based business is located in Tampa, Florida on the campus of the University of South Florida (USF Connect). We are operated by a group of researchers and scientists including cancer biologists, neuroscientists, chemists, and statisticians.
Amyloid beta (Aβ40, Aβ42) and Tau peptides (partnered with Biomer Tech Inc.);
Anti-Aβ (40, 42)antibodies, anti-Alpha Synuclein antibodies, and anti-GPC1 antibodies, and well as anti-HIV gp41 and gp120 antibodies;
Recombinant Aβ, recombinant alpha synuclein, and GPC1 proteins et al;
Sandwich ELISA kits quantitative detection for Aβ40, and 42, alpha synuclein, and GPC1 protein;
ELISA kits for cytokines;
Nano-formula of CBD, melatonin, and coffee for oral and intranasal spray;
Dendritic cell vaccines for animal studies:
Aβ-amyloid based vaccine for Alzheimer’s disease and alpha synuclein-based vaccine for Parkinson’s disease.
The novelty of the patent
We have licensed a patent through USF: “an antigen stimulation dendritic cell vaccine”. It is a platform for immunotherapies, such as we can develop for cancer and neurological diseases.
The advantage of the dendritic vaccine can overcome aging-related immune tolerance and bridge the innate immunity and acquired immunity to control overreaction to a vaccine. Dendritic cell vaccines have been used in clinical trials for years and have shown no significant adverse effects.
Opportunities for Investment